Patrick Branch, head of Japan and APAC business development at Nxera Pharma, Japan’s most innovative and nimble biopharma ...

Immedica Pharma acquires Marinus Pharmaceuticals for $151 million, gaining the rare disease treatment Ztalmy and expanding ...

China’s National Medical Products Administration (NMPA) has approved Astellas Pharma’s Vyloy (zolbetuximab), in combination ...

Anglo-Swedish drugmaker AstraZeneca has announced that new, positive, long-term results from the pivotal ALPHA Phase III ...

Japanese drugmaker Otsuka Pharmaceutical has announced that the European Medicines Agency (EMA) has accepted for review the ...

Anthem Biosciences files for a $397 million IPO amid India’s record-breaking year for public listings. The Bengaluru-based ...

Denmark-based macrocycle-drug developer Orbis Medicines today announces the close of a 90 million euros ($94 million) Series ...

Alon Natanson, a business leader and alumnus of the Hebrew University of Jerusalem, has been appointed chief executive ...

Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.

Californian biotech General Proximity announced its emergence from stealth on Friday, unveiling its proprietary OmniTAC ...

China’s National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of Dovbleron ...

Pfizer ends its collaboration with Sangamo Therapeutics on a haemophilia A gene therapy despite strong Phase III results and ...